AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

Core Viewpoint - AIM ImmunoTech Inc. has entered into an agreement with Thermo Fisher Scientific to design a Phase 3 clinical trial for its drug Ampligen, aimed at treating late-stage pancreatic cancer, following promising results from the ongoing Phase 2 DURIPANC trial [1][2]. Group 1: Clinical Trial Developments - The Phase 2 DURIPANC clinical trial, which involves Ampligen and AstraZeneca's durvalumab, is showing positive results in terms of Progression-Free Survival (PFS), Overall Survival (OS), and safety [3]. - The DURIPANC study is an exploratory, open-label trial expected to enroll up to 25 subjects, conducted in collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands [3]. Group 2: Company Strategy and Goals - AIM's CEO emphasized the importance of moving forward with the development of Ampligen for pancreatic cancer, highlighting the drug's potential to address a significant unmet medical need [2]. - The company has published an updated corporate presentation outlining its goal for new drug approval for Ampligen, detailing its research and development efforts in pancreatic cancer [2]. Group 3: Product Information - Ampligen (rintatolimod) is described as a dsRNA and highly selective TLR3 agonist immuno-modulator, which has demonstrated broad-spectrum activity in clinical trials [4].